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httpcense.Abstract Background: Systemic lupus erythematosus (SLE) involves different body organs
including lungs, however, there is limited information on silent pulmonary involvement in systemic
lupus, so, the purpose of this study is to identify both occult and manifest pulmonary complication
in patients with SLE and its correlation with disease activity parameters, and high resolution com-
puted tomography (HRCT) ﬁndings.
Method: Fifty female patients fulﬁlling the ACR criteria for SLE were enrolled and evaluated
using chest X-ray, echocardiography (Echo), pulmonary function tests (PFT) and HRCT of the
chest to ﬁnd out the pulmonary involvement.
Results: This study was carried out on 50 SLE female patients, 24 (48%) of them were with
pulmonary manifestations and 26 (52%) of them were without pulmonary manifestations. HRCT
showed abnormalities in 32 patients in contrast to chest X-ray which showed abnormalities only in
22 patients (P-value < 0.05). Mild pulmonary hypertension was found in 4 (8%) patients. Pulmon-
ary function tests indicated that the majority of the patients (80%) presented with restrictive pattern
with equal percentage of both symptomatic and asymptomatic patients. Diffusion defect was in
56% of all studied patients. Few patients showed obstructive pattern (4%). Residual volume was
high in most of the patients.617612; fax: +20 862342505.
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464 H.A. Mohammad et al.Conclusion: Pulmonary involvement is present in a signiﬁcant number of SLE patients as
detected by PFTs and HRCT, however, the majority of patients were asymptomatic. Decreased dif-
fusing capacity of females with systemic lupus is prevalent.
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Systemic lupus erythematosus (SLE) is an autoimmune disease
which involves many body organs [1]. Respiratory abnormality
is a prevalent ﬁnding in patients with systemic lupus [1]. The
most common pulmonary presentations in patients include
pleuritis, acute pneumonitis, chronic pulmonary interstitial
disease, diaphragm weakness, and alveolar hemorrhage [2,3].
Mild cases of pulmonary involvement without clinical presen-
tation which can remain hidden from the patient and the phy-
sician are not rare [4]. Using more sensitive investigations
including HRCT and tests of lung function is a valuable assess-
ment method for investigating lung involvement without clin-
ical symptoms [4].
The results of lung function tests in patients with systemic
lupus demonstrate various disorders [4–6]; the previously con-
ducted studies have generally focused on symptomatic patients
and almost always examined simple spirometry with forced vi-
tal capacity, however. Only some recent studies have measured
the capability of gas transfer in lungs with an emphasis on car-
bon monoxide (lung transfer factor) and its decrease in lupus
patients with pulmonary symptoms [7]. However, few data
are available that reported total lung capacity and residual
air in lupus patients. In addition, there are contradictory pieces
of evidence on the relationship between tests of lung function
and serological and chronic ﬁndings in the lupus disease [8–10].
Lung investigations in patients suffering from lupus are always
limited to a small number of patients which has, undoubtedly,
affected the obtained results. Therefore, more studies on a
large number of patients can be more revealing in terms of
evaluating disorders through lung function tests, especially dif-
fusing capacity of carbon monoxide in lungs.
Several studies have shown the increased sensitivity of
HRCT of the chest compared with plain chest radiography
in identifying interstitial lung disease. HRCT improves visual-
ization of small parenchymal structures allowing evaluation
and grading of the severity of diffuse inﬁltrative lung disease
[11,12].
The aim of current study is to evaluate whether HRCT
helps in early detection of pulmonary involvement in SLE,
and to clarify the characterization of pulmonary function tests
(PFT), especially carbon monoxide diffusion capacity
(DLCO), and their correlation with clinical features and
immunological markers in patients with SLE.
Patients and methods
The study was carried out on ﬁfty (50) female patients with
SLE recruited from both outpatients and inpatient of Rheu-
matology, and Internal medicine departments in Al-Minya
university hospital from August 2008 to September 2011.
Inclusion criteria: all patients were diagnosed according to
1982 revised criteria of the American College of Rheumatology(ACR) for SLE [13]. The protocol was approved by the
institutional ethics committee, and informed consent was ob-
tained from the patients. Detailed history regarding cough
(with or without expectoration), respiratory difﬁculty, chest
pain and hemoptysis were recorded.
Exclusion criteria: patients were excluded if they were
known to have interstitial lung disease (occupational hazard)
or if they were pregnant.
The following were done for all patients:
1- Routine laboratory investigation, Immunological mark-
ers: antinuclear antibody (ANA), Anti-double strand
DNA antibody (dsDNA), C – reactive protein, comple-
ments (C3 and C4).
2- Pulmonary function tests which include: static lung vol-
umes, diffusion, and spirometric tests.
3- Imaging: chest radiograph and high resolution com-
puted tomography (HRCT) of the chest.
Echo examination was done for all patients at rest. Echo
was used to evaluate cardiac morphology and ﬂow abnormal-
ities. Pulmonary arterial hypertension (PAH), deﬁned by a pul-
monary artery systolic pressure (PASP) >30 mmHg [14].
Pulmonary function tests
Pulmonary function tests were done to all patients at the time
of the examination setting and wearing nose clip using ZAN
300 co-diffusion (Germany).
Flow volume loop was performed in accordance with
American Thoracic Society (ATS) [15] guidelines by one tech-
nician. The instrument met the accuracy criteria of the ATS.
Spirograms were repeated until three acceptable tests or eight
maneuvers were obtained [16]. Lung volumes were measured
by the methane rebreathing method according to standardized
techniques and gas transfer (DLCO) was measured using the
single-breath technique. The DLCO was corrected for lung
volumes and hemoglobin levels. Observed values were com-
pared with those predicted for age, sex, and height for each
individual. Results of the pulmonary function tests were ex-
pressed as a percentage of the predicted value (% pred.). Pul-
monary function parameters were considered abnormal when
they were below 80% of the predicted value according to stan-
dard of ATS [17].
The FEV1/FVC ratio was considered obstructive if it was
less than 75 percent. Reduction in the FVC with a normal or
elevated FEV1-to-FVC ratio should trigger further diagnostic
workup to rule out restrictive lung disease. Measuring the TLC
and residual volume (RV) can conﬁrm restriction suggested by
spirometry based on the criteria of the American Thoracic
Society [17].
All patients underwent HRCT examination on the same
day that they performed PFTs using CT general electric pro-
Table 2 Comparison between X-ray ﬁndings and HRCT in all
studied patients.
Finding X-ray total = 50 HRCT total = 50 P value
Normal 28 18 0.02*
Pleural disease 6 14 0.02*
Interstitial pattern 4 26 0.00007*
Airway disease 6 2 0.07
Pneumonia 2 8 0.04
* Signiﬁcant P-value < 0.05.
Detection of pulmonary involvement in lupus patients 465speed plus 4.00 with following scan protocol: thin slices (1 mm)
and a high spatial frequency reconstruction algorithm.
The following CT signs were evaluated
 Pulmonary parenchymal nodules with or without
calciﬁcations.
 Linear opacities.
 Increased lung density-(a) Ground glass opacities (b)
Consolidation.
 Honey combing.
 Pleural thickening.
Statistical analysis
Data were coded, entered, and analyzed by SPSS (statistical
package for the social sciences for windows version 13). [18].
Two-tailed tests were used throughout, and P values less
than 0.05 were considered signiﬁcant. (1) Descriptive statistics:
the range, means, and standard deviation were calculated for
interval and ordinary variables, and frequencies and percent-
ages for categorical variables [19]. (2) Group comparison: com-
parisons were done by two procedures: student’s t-test, and the
chi-square (v2) test. (3) Correlations: the bivariate correlations
procedure computes Pearson’s correlation coefﬁcient with its
signiﬁcance levels.
Results
This study was carried out on 50 SLE female patients fulﬁlling
the updated ACR classiﬁcation criteria for SLE [13], 24 (48%)
of them were with pulmonary manifestation and 26 (52%) of
them were without pulmonary manifestation. The patients’
age ranged between 15 and 51 years with a mean of
24.2 ± 7.4. The disease duration ranged between 2 and
120 months with a mean of 28.4 ± 24.6.Table 1 Characteristic data of all studied patients.
Item Total no. (50)
Clinical manifestation
Cough + expectoration 24 (48%)
Heamoptysis 10 (20%)
Dyspnea 24 (48%)
Wheezes 4 (8%)
Chest pain 18 (36%)
Laboratory ﬁndings
C3 < 70 mg/dl 37 (74%)
C4 < 13 mg/dl 36 (72%)
ANA> 1:160 36 (72%)
Ant.ds DNA> 75(Iu/ml) 36 (72%)
PFT
Normal 8(16%)
Restrictive 40 (80%)
Diﬀusion defect 28 (56%)
Obstructive 2 (4%)
Echo ﬁndings
Pericardic eﬀusion 10 (20%)
Valvular disease 18 (36%)
Myocarditis + diastolic dysfunction 6 (12%)
Pulmonary hypertension 4 (8%)The clinical chest data, laboratory, PFT and echo ﬁnding of
all studied patients are presented in Table 1.
The most prevalent symptoms for respiratory involvement
were cough and exertional dyspnea in 26 (52%) patients, and
chest pain in 18/50 (36%) patients. Echocardiographic study
proved normal ﬁnding in 16/50 (32%) patients, pericardial
effusion in 10 (20%), valvular disease in 18/50 (36%), myocar-
ditis in 2 (4%), diastolic dysfunction in 4/50 (8%), and pul-
monary hypertension in 4/50 (8%) patients with mean value
38.9 ± 1.4.
Pulmonary function tests in all studied patients revealed
that the majority of the patients (80%) presented with restric-
tive pattern with equal percentage of both symptomatic and
asymptomatic. Diffusion defect was found in 28/50 (56%) of
all studied patients. Few patients showed obstructive pattern
(4%) and normal pattern was in 8 (16%) patients (Table 1).
Table 2 shows a comparison between CXR and HRCT
ﬁndings in all group studies. There was a signiﬁcant difference
in detection of abnormalities using ordinary CXR and HRCT
(p< 0.005).
Table 3 shows HRCT ﬁnding. Normal HRCT was found in
a total of 18 patients (36%). Pleural affection in 14/50 (28%); 6
in symptomatic and 8 in asymptomatic patients. More than
half of the patients (52%) had interstitial pattern divided as
40% were symptomatic and the others were asymptomatic
(Fig. 1). Pneumonia was in 8 (16%) with equal percentage in
symptomatic and asymptomatic patients (Fig. 2), airway dis-
ease was only in 2 (4%) asymptomatic patients.
Table 4 shows a decrease in the mean value of VC being
62.58 ± 14.6 in symptomatic patients and 66.46 ± 16.6 in
asymptomatic patients with no signiﬁcant difference. On the
other hand, a signiﬁcant difference was detected in TLC % va-
lue as being more in asymptomatic patients with mean value
85.92 ± 19.98. Increased residual volume (RV) and RV/TLC
in both symptomatic and asymptomatic groups indicate air-
way trapping. Diffusion test shows a defect in percent mean
value of DLCO in both symptomatic patients and asymptom-
atic patients with no signiﬁcant difference. Dynamic PFTs
show also a defect in all parameters with no signiﬁcant differ-
ences in the mean values of both symptomatic and asymptom-
atic groups of patients.
All patients with normal HRCT ﬁndings, those with pleural
affection, and those with interstitial pattern show a decrease in
the mean percent value of VC with no signiﬁcant difference.
On the other hand, a signiﬁcant difference was found among
these groups of patients in mean value of TLC and DLCO
being highest in patients with normal HRCT and lowest in pa-
tients with, interstitial pattern in HRCT (Table 5).
No signiﬁcant correlation was found between mean percent
values of VC, TLC, DLCO and FEV1 and low level of both C3
Table 3 HRCT ﬁndings in symptomatic patients (with clinically pulmonary ﬁndings) and asymptomatic patients (those who are
without clinically pulmonary ﬁndings).
HRCT ﬁndings Symptomatic No = (24) Asymptomatic No = (26) Total No = (50)
Normal 10 (20%) 8 (16%) 18 (36%)
Pleural disease
1-Pleural eﬀusion 2 4
2-Pleural thickening 2 2
3-Sub pleural band 2 2
Total 6 (12%) 8 (16%) 14 (28%)
ILD
1-Interstitial thickening 2 0
2-Parenchymal band 2 2
3-Parenchymal nodules 2 0
4-Thick inter-lobular septa 6 2
5-Ground glass appearance 4 0
6-Thick ﬁssure 4 2
Total 20 (40%) 6 (12%) 26 (52%)
Air way disease
Thick bronchial wall 0 (0%) 2 (4%) 2 (4%)
Pneumonia
Air space consolidation 4 (8%) 4 (8%) 8 (16%)
Figure 1 Axial HRCT of the chest of a female patient 35 years
with segmental bronchectasis, thickened interlobar and interlob-
ular ground glass appearance septae and thickened transverse
ﬁssure.
Figure 2 Axial HRCT of the chest of a female patient 20 years
with SLE that showed posterior basal segment air space consol-
idation and thickened transverse ﬁssure.
466 H.A. Mohammad et al.and C4 and +ve anti-DNA, but a signiﬁcant correlation was
noticed between patients with +ve ANA and DLCO Table 6.
Discussion
Systemic lupus erythematosus (SLE) is a clinical syndrome
with a complex, multi-factorial etiology, and it is characterized
by inﬂammation and involvement of multiple organ systems
[20]. Systemic lupus erythematosus (SLE) most commonly af-
fects women of childbearing age; women are afﬂicted 6 to 10
times more often than men [21].This study included 50 female patients with systemic lupus
erythematosus, their mean age was 24.2 ± 7.4 (ranging from
15 to 51 years) and a mean disease duration of 28.4 ± 24.65
(ranging from 2 to 120 months). This is in agreement with
the study of Kakati et al. [22] who carried on a similar study
with the mean age of lupus patients being 26.18 years, while,
in Peter et al. [10] and Amra et al. [23] studies the range of
age was extended to above 60 years.
The prevalence of respiratory manifestations in patients
with systemic lupus erythematosus (SLE) varies depending
on several factors, including methods of diagnosis, time of fol-
low-up [24]. In the present study, the symptoms referable to
respiratory system were present in 24/50 patients (48%) and
Table 4 The mean values of pulmonary functions parameters in symptomatic patients (with clinically pulmonary ﬁndings) and
asymptomatic patients (those who are without clinically pulmonary ﬁndings).
Pulmonary function test Symptomatic (No = 24) mean ± SD Asymptomatic (No = 26) mean ± SD P value
Static parameters
VC (%) 62.58 ± 14.6 66.46 ± 16.6 0.3
RV (%) 146.16 ± 62.01 139.84 ± 66.75 0.7
RV/TLC 54.33 ± 14.15 46.76 ± 13.92 0.06
TLC (%) 72.58 ± 26.31 85.92 ± 19.98 0.04*
Diﬀusion
DLCO (%) 63.38 ± 22.41 71.91 ± 16.97 0.1
KCO (DLCO/AV) (mmol/kPa/min/L) 1.74 ± 27 1.65 ± 0.26 0.2
Dynamic parameters
FVC (%) 60.91 ± 15 66.69 ± 14.63 0.1
FEV1 (%) 61.83 ± 13.55 66.76 ± 10.8 0.1
FEV1/FVC (%) 94.5 ± 5.2 91.07 ± 12.08 0.2
MEF 25–75% 62.91 ± 20.38 68 ± 16.45 0.3
* Signiﬁcant P-value < 0.05.
Table 6 Correlation between levels of different activity markers and PFTs parameters.
Inﬂammatory markers Pulmonary function parameters (%) Mean ± SD of Positive cases Mean ± SD of negative cases P value
Low C3 VC 64.5 ± 16.2 57.3 ± 18.3 0.1
TLC 80.5 ± 28.2 85.9 ± 19.2 0.8
DLCO 66.8 ± 20.9 72.9 ± 26.9 0.4
FEV1 61.6 ± 13.9 64.2 ± 12.5 0.5
Low C4 VC 64.4 ± 16.4 58.1 ± 17.8 0.2
TLC 80.3 ± 27.9 79.1 ± 21.2 0.8
DLCO 66.3 ± 21.1 73.5 ± 26.01 0.3
FEV1 61.4 ± 14.02 64.6 ± 12.1 0.4
ANA VC 63.3 ± 15.5 60.9 ± 20.6 0.6
TLC 77.6 ± 28.2 85.9 ± 19.2 0.3
DLCO 64.4 ± 20.1 78.3 ± 25.9 0.04*
FEV1 60.2 ± 13.9 67.9 ± 11.01 0.07
Anti dsDNA VC 64.4 ± 16.4 58.1 ± 17.8 0.2
TLC 80.3 ± 27.9 79.1 ± 21.2 0.8
DLCO 66.3 ± 21.1 73.5 ± 26.01 0.3
FEV1 61.4 ± 14.02 64.8 ± 12.1 0.4
* Signiﬁcant P-value < 0.05.
Table 5 Correlations between the changes in pulmonary functions and HRCT ﬁndings in all patients.
PFTs HRCT ﬁndings (No. of patients) Mean ± Std. deviation P value
VC Pleural (14) 60.57 ± 15.747 .200
ILD (26) 66.29 ± 7.457
Normal (18) 65.56 ± 8.333
TLC Pleural (14) 61.67 ± 18.117 .000*
ILD (26) 55.38 ± 15.071
Normal (18) 87.22 ± 26.505
FVC Pleural (14) 64.43 ± 9.196 .700
ILD (26) 62.58 ± 10.185
Normal (18) 61.00 ± 15.107
TLCO Pleural (14) 61.00 ± 3.766 .007*
ILD (26) 60.27 ± 14.317
Normal (18) 74.44 ± 18.325
* Signiﬁcant P-value < 0.05.
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468 H.A. Mohammad et al.all of them suffered from cough, and exertional dyspnea, while
chest pain was in 18/50 patients (36%), heamoptysis in 10
(20%), and wheezes in 4/50 (8%). In the study of Miriam
et al. [25] seven female patients and one male patient presented
clinically with dyspnea on exertion (50%), and non-productive
cough was in 25%. Two patients were asymptomatic and an-
other two had bibasilar rales.
Regarding ECHO ﬁndings, mild pulmonary hypertension
was detected in only 4 patients (8%). Two of them were with
mitral regurge and one diagnosed as ILD and the other one
diagnosed by exclusion most probably due to pulmonary vas-
culitis. In the study of Menon et al. [26], 5 patients over
10 years of total 300 patients were found to have pulmonary
hypertension not attributed to cardiac, pulmonary thrombotic
or other disease. But, Boopathy et al. [27] found that higher
percentage of patient with pulmonary artery hypertension
(PAH) out of 20 patients, 9 (45%) had primary PHT, and 11
(55%) had secondary PHT which includes 3 (28%) with pul-
monary thromboembolism, 3 (28%) with valve lesions, and 5
(40%) with ILD. Six (30%) patients had mild PHT, 8 (40%)
had moderate, and 6 (30%) had severe PHT.
In this study, high resonance CT was found to be more sen-
sitive than plain chest X-ray in diagnosing ILD, plural affec-
tion and pneumonia, as 26 (52%) patients showed ILD
pattern in HRCT compared with 4 (8%) patients on plain
chest X-ray. This is in an agreement with Anwar et al. [28]
study in which HRCT abnormality was found in 25 patients
(78.12%) compared with 8 patients (24.97%) on plain chest
X-rays. Ghosh et al. also concluded that 50% of ILDs diag-
nosed by scan chest X-rays were normal. [29].
In the present study, HRCT detected early pulmonary
affection as out of 26 patients who had normal clinical exam-
ination 18/26 (69.2%) patients had HRCT abnormalities. In
the study of Kakati et al. [22] out of 26 patients who had a nor-
mal examination, normal chest X-ray, and normal PFT, only
10 (38%) patients had HRCT abnormalities; the discrepancy
may be because most of our cases had abnormal PFT.
In the current work, more than half of the patients (26/50)
show interstitial pattern and 6/50 (12%) patients were asymp-
tomatic followed by, pleural disease in 14 (28%) and these
ﬁndings are in agreement with that of Fenlon et al. [30] who
reported ILD in 53% of patients on HRCT and 33% had a
deﬁnitive diagnosis of ILD. Jeffery et al. [31] found that ILD
is present in at least a third of asymptomatic patients and air-
way abnormalities are seen in one ﬁfth. The study of Kakati
et al. [22] states that ILD was detected in 39.47%.
In the present study, 4% of the patients showed airway
affection in the form of bronchial wall thickening and bronchi-
ectasis on chest HRCT but in the study of Fenlon et al. [30]
they were detected in approximately 20% of lupus patients,
but they are commonly clinically silent. Bronchiolar disorders
in lupus are not rare, Fenlon et al. study shows a higher per-
centage than our study.
Pulmonary function testing (PFT) in SLE patients has been
used for many years as the diagnostic modality for lung
involvement. In the present study, most of the patients were
presented with abnormal functions where normal pattern
was only in 8/50 (16%) patients. Majority of our patients
(80%) showed restrictive pattern, and half of them were with-
out clinical pulmonary ﬁndings, this was conﬁrmed by im-
paired VC, FVC with no signiﬁcant difference if comparedwith those with clinical pulmonary ﬁndings (Tables 1 and 4).
Increased residual volume (RV) and RV/TLC in both symp-
tomatic and asymptomatic groups indicated small airway
affection. Airway trapping in these patients can be explained
by bronchiolitis [32].
Impaired diffusion was noticed in 28/50 (56%) patients
with a concomitant restrictive ventilatory defect, 24% of all
studied patients had also a decrease in KCO and were diag-
nosed as ILD. In the study of Danella et al. [33] DLCO was
impaired in 19 (54%) of patients and 10 of this patients did
not have any other pulmonary function abnormality.
On the other hand, in the current study few patients had
obstructive pattern (4%), while, in Masso et al. [34] study;
there was association between collagen vascular disease and
small airway diseases or interstitial involvement even in pa-
tients with neither smoking history nor abnormal ﬁnding in
chest X-ray. They, also, noticed in subjects with symptoms
or abnormal shadows in chest X-ray DLCO percentage de-
creased. Diffusion capacity is usually disturbed by interstitial
involvement and the ventilation perfusion inequality, which
is frequently caused by small airway affection in the form of
air trapping and increase RV. This affection disturbs diffusion
capacity by increasing areas of low ventilation-perfusion ratio
or causing vasoconstriction by alveolar hypoxemia. [30].
Our study proved that PFTs are sometimes more sensitive
in early detection of pulmonary involvement as the 18 patients
who had normal HRCT ﬁndings had a defect in VC and FVC
with no signiﬁcant differences if compared with other groups
with HRCT abnormality (Table 5). In contrast to our study,
in the study of Danella et al. [33] there is no signiﬁcant corre-
lation between radiological ﬁnding and PFTs abnormality.
Several studies have attempted to correlate PFT with clini-
cal and serological parameters of SLE with conﬂicting results.
Silberstein et al. [5] in his study, reported that no correlation
was found in either the classiﬁcation or severity of the pulmon-
ary function abnormality when compared with other measures
of lupus activity, such as serology, immune complexes in skin
biopsy, and renal biopsy.
In the present work, no signiﬁcant correlation is found be-
tween C3, C4, anti-DNA levels and PFT including VC, TLC,
DLCO and FEV1. On the other hand, a signiﬁcant inverse cor-
relation was found between ANA level and DLCO (P< 0.05).
This agrees with the study of Babak et al. [32] who concluded
that the activity of lupus disease was found to be inversely pro-
portional to the amount of diffusing capacity of the lungs for
carbon monoxide among patients suffering from lupus disease
with pulmonary involvement.
In conclusion, pulmonary involvement is present in a signif-
icant number of SLE patients, who are often asymptomatic,
with normal chest X-ray or HRCT. HRCT ﬁndings in SLE
suggest that ILD and pleural disease are common thoracic
manifestations of SLE whereas airway disease is less common.
PFTs ﬁndings indicate that small airway diseases and a de-
crease in diffusing capacity are not rare in lupus patients, even
if they had neither a smoking history nor abnormal ﬁndings in
their chest X-ray ﬁlms and can be affected by disease activity.Conﬂict of interest
None declared.
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